Fentanyl
Approved · FDA / EMAAlso known as 1-Phenethyl-4-(N-phenylpropionamido)piperidine, 1-phenethyl-4-N-propionylanilinopiperidine, Abstral, Actiq+22 more
1-Phenethyl-4-(N-phenylpropionamido)piperidine, 1-phenethyl-4-N-propionylanilinopiperidine, Abstral, Actiq, Droperidol-Fentanyl, Duragesic, Fentanyl CII, Fentora, Innovar, Ionsys, Lazanda, N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide, N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide, N-(1-phenethyl-4-piperidyl)propionanilide, N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide, N-phenethyl-4-(N-propionylanilino)piperidine, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide, Onsolis, Phentanyl, Sublimaze, Subsys, Fentanil, Fentanila, Fentanilo, FentaNYL Citrate, Fentanylum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Many U.S. teens underestimate fentanyl’s deadly risk
Supplemental approval: FENTANYL (ANDA076258)
Supplemental approval: FENTANYL (ANDA077449)
Supplemental approval: FENTANYL (ANDA202097)
Supplemental approval: FENTANYL TRANSDERMAL (ANDA077154)
New fentanyl vaccine blocks deadly overdoses before they start
Co-occurring illicit fentanyl use and psychiatric disorders in emergency department patients.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: PecFent is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a… Show full indicationShow less
PecFent is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equi-analgesic dose of another opioid for a week or longer.
Indication: Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory… Show full indicationShow less
Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
Indication: Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a… Show full indicationShow less
Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes7
Journals, researchers & institutions
- Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver1
- Nature communications1
- Scientific reports1
- Abrahao A1
- Agostoni M1
- Arcidiacono PG1
- Aubert I1
- Black SE1
- Downs A1
- Fanti L1
- Gemma M1
- Department of Laboratory Medicine and Pathobiology1
- Harquail Centre for Neuromodulation1
- Heersink School of Medicine1
- Institute of Biomaterials and Biomedical Engineering1
- Sunnybrook Health Sciences Centre1
- Sunnybrook Research Institute1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Fentanyl in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.